Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More

BACKGROUND: This study aimed to analyze the economics of pembrolizumab plus chemotherapy as first-line treatment in patients with esophageal squamous cell carcinoma (ESCC) and programmed cell death-Ligand 1 (PD-L1) combined positive score (CPS) of 10 or more in China. METHODS: Based on the advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhiwei, Lin, Jingrong, Zhu, Huide, Cai, Hongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237361/
https://www.ncbi.nlm.nih.gov/pubmed/35774581
http://dx.doi.org/10.3389/fpubh.2022.893387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237361/
https://www.ncbi.nlm.nih.gov/pubmed/35774581
http://dx.doi.org/10.3389/fpubh.2022.893387

Ejemplares similares